<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3001">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01685801</url>
  </required_header>
  <id_info>
    <org_study_id>VX12-770-113</org_study_id>
    <nct_id>NCT01685801</nct_id>
  </id_info>
  <brief_title>Pilot Study Testing the Effect of Ivacaftor on Lung Function in Subjects With Cystic Fibrosis and Residual CFTR Function</brief_title>
  <official_title>A Pilot Study Testing the Effect of Ivacaftor on Lung Function in Subjects With Cystic Fibrosis, Residual CFTR Function, and FEV1 ≥40% Predicted</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vertex Pharmaceuticals Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vertex Pharmaceuticals Incorporated</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multiple within subject crossover study to evaluate the effect of ivacaftor
      on lung function in subjects aged 12 years and older with cystic fibrosis (CF) who have
      phenotypic or molecular evidence of residual CF transmembrane conductance regulator (CFTR)
      function.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      CFTR Mutations associated with residual CFTR function or defective mRNA splicing include the
      following:

      R117H, E56K, P67L, D110E, D110H, R117C, R347H, R352Q, A455E, D579G, S945L, L206W, R1070W,
      F1074L, D1152H, S1235R, D1270N, 2789+5G-&gt;A, 3849+10kbC-&gt;T, 3272-26A-&gt;G, 711+5G-&gt;A, 3120G-&gt;A,
      1811+1.6kbA-&gt;G, 711+3A-&gt;G, 1898+3A-&gt;G, 1898+1G-&gt;A, 1717-1G-&gt;A, 1717-8G-&gt;A, 1342-2A-&gt;C,
      405+3A-&gt;C, 1716G/A 1811+1G-&gt;C, 1898+5G-&gt;T, 3850-3T-&gt;G, IVS14b+5G-&gt;A, 1898+1G-&gt;T, 4005+2T-&gt;C,
      621+3A-&gt;G, 621+1G-&gt;T
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Caregiver), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Relative change from baseline in percent predicted forced expiratory volume in 1 second (FEV1) after 2 weeks of treatment</measure>
    <time_frame>baseline and 2 weeks of treatment</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in lung clearance index (LCI) after 2 weeks of treatment</measure>
    <time_frame>baseline and 2 weeks of treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relative change from baseline in percent predicted FEV1 after 8 weeks of treatment</measure>
    <time_frame>baseline and 8 weeks of treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in LCI after 8 weeks of treatment</measure>
    <time_frame>baseline and 8 weeks of treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in sweat chloride after 8 weeks of treatment</measure>
    <time_frame>baseline and 8 weeks of treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in weight after 8 weeks of treatment</measure>
    <time_frame>baseline and 8 weeks of treatment</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety, as determined by adverse events and vital signs</measure>
    <time_frame>baseline through 28 weeks (follow-up visit)</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">24</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ivacaftor &gt; placebo &gt; ivacaftor &gt; placebo &gt; ivacaftor (open-label period)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ivacaftor &gt; placebo &gt; placebo &gt; ivacaftor &gt; ivacaftor (open-label period)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>placebo &gt; ivacaftor &gt; ivacaftor &gt; placebo &gt; ivacaftor (open-label period)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sequence 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>placebo &gt; ivacaftor &gt; placebo &gt; ivacaftor &gt; ivacaftor (open-label period)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ivacaftor</intervention_name>
    <description>150 mg tablet for oral use, administered every 12 hours</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
    <other_name>Tradename: KALYDECO</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>tablet for oral use, administered every 12 hours</description>
    <arm_group_label>Sequence 1</arm_group_label>
    <arm_group_label>Sequence 2</arm_group_label>
    <arm_group_label>Sequence 3</arm_group_label>
    <arm_group_label>Sequence 4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male or female subjects with confirmed diagnosis of CF

          -  Clinical evidence of residual CFTR function based on any 1 of the following:
             1)Clinically documented residual exocrine pancreatic function, 2)Sweat chloride value
             ≤80 mmol/L at screening, or 3) Age of diagnosis ≥12 years and at least 1 copy of a
             CFTR mutation associated with residual CFTR function or defective mRNA splicing

          -  FEV1 ≥40%

          -  12 years of age or older

          -  Willing to agree to meet the contraception requirements

          -  Able to swallow tablets

        Exclusion Criteria:

          -  A copy of any of the following CFTR mutations: G551D, G178R, S549N, S549R, G551S,
             G970R, G1244E, S1251N, S1255P, G1349D

          -  Unable to perform spirometry

          -  An acute upper or lower respiratory infection, pulmonary exacerbation, or changes in
             therapy (including antibiotics) for pulmonary disease within 4 weeks before Day 1

          -  Ongoing participation in another therapeutic clinical study or prior participation in
             an investigational drug study within the 30 days prior to screening
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jerry Nick, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Jewish Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <lastchanged_date>October 17, 2013</lastchanged_date>
  <firstreceived_date>September 6, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cystic Fibrosis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
